Form 4: Crinetics Pharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
Richard Scott Struthers, President & CEO and a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on August 7, 2026.
Summary
- Option exercise/conversion: acquired 3,969 Common Stock at $25.19 ($99,979) on August 7, 2026; holds 408,747 after (Direct).
- Option exercise/conversion: acquired 4,422 Common Stock at $22.61 ($99,981) on August 7, 2026; holds 413,169 after (Direct).
- Option exercise/conversion: acquired 6,542 Common Stock at $15.29 ($100,027) on August 7, 2026; holds 419,711 after (Direct).
- Option exercise/conversion: acquired 4,995 Common Stock at $20.02 ($100,000) on August 7, 2026; holds 424,706 after (Direct).
- Option exercise/conversion: disposed of 3,969 Stock Option (Right to Buy) on August 7, 2026; holds 172,281 after (Direct).
- Option exercise/conversion: disposed of 4,422 Stock Option (Right to Buy) on August 7, 2026; holds 195,578 after (Direct).
- Option exercise/conversion: disposed of 6,542 Stock Option (Right to Buy) on August 7, 2026; holds 259,058 after (Direct).
- Option exercise/conversion: disposed of 4,995 Stock Option (Right to Buy) on August 7, 2026; holds 244,205 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Richard Scott Struthers — Director, Officer (President & CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Option exercise/conversion | Common Stock | 3,969 | $25 | $100.0K | 408,747 |
| 2026-08-07 | Option exercise/conversion | Common Stock | 4,422 | $23 | $100.0K | 413,169 |
| 2026-08-07 | Option exercise/conversion | Common Stock | 6,542 | $15 | $100.0K | 419,711 |
| 2026-08-07 | Option exercise/conversion | Common Stock | 4,995 | $20 | $100.0K | 424,706 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 3,969 | — | — | 172,281 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 4,422 | — | — | 195,578 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 6,542 | — | — | 259,058 |
| 2026-08-07 | Option exercise/conversion | Stock Option (Right to Buy) | 4,995 | — | — | 244,205 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Option exercise/conversion (3,969 shares) |
| 2026-08-07 | Option exercise/conversion (4,422 shares) |
| 2026-08-07 | Option exercise/conversion (6,542 shares) |
| 2026-08-07 | Option exercise/conversion (4,995 shares) |
| 2026-08-07 | Option exercise/conversion (3,969 shares) |
| 2026-08-07 | Option exercise/conversion (4,422 shares) |
| 2026-08-07 | Option exercise/conversion (6,542 shares) |
| 2026-08-07 | Option exercise/conversion (4,995 shares) |
Keywords
insider transaction, Form 4, CRNX, Crinetics Pharmaceuticals, Inc., neutral, Richard Scott Struthers
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.